{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:58:18Z","timestamp":1767963498241,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10822-014-9800-9","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T08:46:33Z","timestamp":1413189993000},"page":"1247-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents"],"prefix":"10.1007","volume":"28","author":[{"given":"Vikash","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Durga Prasad","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakil","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Imran","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"9800_CR1","unstructured":"http:\/\/www.cancer.gov\/ . Accessed Dec 2013"},{"issue":"42","key":"9800_CR2","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1206757","volume":"22","author":"T Bogenrieder","year":"2003","unstructured":"Bogenrieder T, Herlyn M (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22(42):6524\u20136536","journal-title":"Oncogene"},{"issue":"11","key":"9800_CR3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd4145","volume":"12","author":"L Galluzzi","year":"2013","unstructured":"Galluzzi L, Kepp O, Heiden MG, Kroemer G (2013) Metabolic targets for cancer therapy. Nat Rev Drug Discov 12(11):829\u2013846","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"9800_CR4","first-page":"583","volume":"5","author":"C Tsatsanis","year":"2000","unstructured":"Tsatsanis C, Spandidos DA (2000) The role of oncogenic kinases in human cancer (review). Int J Mol Med 5(6):583\u2013590","journal-title":"Int J Mol Med"},{"issue":"5","key":"9800_CR5","first-page":"701","volume":"5","author":"D Fabbro","year":"2002","unstructured":"Fabbro D, Garc\u00eda-Echeverr\u00eda C (2002) Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Dev 5(5):701\u2013712","journal-title":"Curr Opin Drug Discov Dev"},{"issue":"5","key":"9800_CR6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"JT Hartmann","year":"2009","unstructured":"Hartmann JT, Haap M, Kopp HG, Lipp HP (2009) Tyrosine kinase inhibitors\u2014a review on pharmacology, metabolism and side effects. Curr Drug Metab 10(5):470\u2013481","journal-title":"Curr Drug Metab"},{"issue":"16","key":"9800_CR7","doi-asserted-by":"crossref","first-page":"8147","DOI":"10.1158\/0008-5472.CAN-05-3489","volume":"66","author":"M Capra","year":"2006","unstructured":"Capra M, Nuciforo PG, Confalonieri S, Quarto M, Bianchi M et al (2006) Frequent alterations in the expression of serine\/threonine kinases in human cancers. Cancer Res 66(16):8147\u20138154","journal-title":"Cancer Res"},{"issue":"4","key":"9800_CR8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/187152006777698132","volume":"6","author":"ZF Tao","year":"2006","unstructured":"Tao ZF, Lin NH (2006) Chk1 inhibitors for novel cancer treatment. Anticancer Agents. Med Chem 6(4):377\u2013388","journal-title":"Anticancer Agents. Med Chem"},{"key":"9800_CR9","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/bcj.2013.1","volume":"3","author":"C Chang-Yew Leow","year":"2013","unstructured":"Chang-Yew Leow C, Gerondakis S, Spencer A (2013) MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J 3:e105. doi: 10.1038\/bcj.2013.1","journal-title":"Blood Cancer J"},{"issue":"4","key":"9800_CR10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1517\/13543784.2012.668527","volume":"21","author":"AL Merkel","year":"2012","unstructured":"Merkel AL, Meggers E, Ocker M (2012) PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs 21(4):425\u2013436","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"9800_CR11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153\u2013166","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"9800_CR12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0092-8674(00)80704-7","volume":"100","author":"P Chen","year":"2000","unstructured":"Chen P, Luo C, Deng Y, Ryan K, Register J et al (2000) The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell 100(6):681\u2013692","journal-title":"Cell"},{"issue":"2","key":"9800_CR13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/mi.11.2.11","volume":"11","author":"P Dent","year":"2011","unstructured":"Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S (2011) CHK1 inhibitors incombination chemotherapy: thinking beyond the cell cycle. Mol Interv 11(2):133\u2013140","journal-title":"Mol Interv"},{"issue":"2","key":"9800_CR14","first-page":"96","volume":"2","author":"JL Adams","year":"1999","unstructured":"Adams JL, Lee D (1999) Recent progress towards the identification of selective inhibitors of serine\/threonine protein kinases. Curr Opin Drug Discov Dev 2(2):96\u2013109","journal-title":"Curr Opin Drug Discov Dev"},{"issue":"20","key":"9800_CR15","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-12-1322","volume":"18","author":"MI Walton","year":"2012","unstructured":"Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G et al (2012) CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res 18(20):5650\u20135661","journal-title":"Clin Cancer Res"},{"issue":"24","key":"9800_CR16","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1021\/jm2007326","volume":"54","author":"JC Reader","year":"2011","unstructured":"Reader JC, Matthews TP, Klair S, Cheung KM, Scanlon J, Proisy N et al (2011) Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. J Med Chem 54(24):8328\u20138342","journal-title":"J Med Chem"},{"issue":"2","key":"9800_CR17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10637-010-9562-8","volume":"30","author":"T Li","year":"2012","unstructured":"Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS et al (2012) A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California cancer consortium trial. Investig New Drugs 30(2):741\u2013748","journal-title":"Investig New Drugs"},{"issue":"41","key":"9800_CR18","doi-asserted-by":"crossref","first-page":"9823","DOI":"10.1021\/bi900258v","volume":"48","author":"D Vanderpool","year":"2009","unstructured":"Vanderpool D, Johnson TO, Ping C, Bergqvist S, Alton G et al (2009) Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry 48(41):9823\u20139830","journal-title":"Biochemistry"},{"issue":"4","key":"9800_CR19","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.bmcl.2008.12.076","volume":"19","author":"A Converso","year":"2009","unstructured":"Converso A, Hartingh T, Garbaccio RM, Tasber E, Rickert K et al (2009) Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 19(4):1240\u20131244","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"9800_CR20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1248\/cpb.57.704","volume":"57","author":"JJ Chen","year":"2009","unstructured":"Chen JJ, Liu TL, Yang LJ, Li LL, Wei YQ, Yang SY (2009) Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors. Chem Pharm Bull (Tokyo) 57(7):704\u2013709","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"7","key":"9800_CR21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00894-009-0630-y","volume":"16","author":"XM Chen","year":"2010","unstructured":"Chen XM, Lu T, Lu S, Li HF, Yuan HL et al (2010) Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors. J Mol Model 16(7):1195\u20131204","journal-title":"J Mol Model"},{"key":"9800_CR22","unstructured":"Ashwell S, Thomas G, Ioannidis S, Janetka J, Lyne P, Su M, Toader D, Yu Y (2005) WO2005066163. Accessed Dec 2013"},{"issue":"24","key":"9800_CR23","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.1016\/j.bmcl.2010.10.105","volume":"20","author":"L Zhao","year":"2010","unstructured":"Zhao L, Zhang Y, Dai C, Guzi T, Wiswell D et al (2010) Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors. Bioorg Med Chem Lett 20(24):7216\u20137221","journal-title":"Bioorg Med Chem Lett"},{"key":"9800_CR24","unstructured":"SYBYL7.1 Tripos Inc., St. Louis, MO, 63144, USA"},{"key":"9800_CR25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/ci00017a025","volume":"34","author":"T Hurst","year":"1994","unstructured":"Hurst T (1994) Flexible 3D searching: the directed tweak technique. J Chem Inf Comput Sci 34:190\u2013196","journal-title":"J Chem Inf Comput Sci"},{"issue":"2","key":"9800_CR26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8","volume":"37","author":"B Kramer","year":"1999","unstructured":"Kramer B, Rarey M, Lengauer T (1999) Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37(2):228\u2013241","journal-title":"Proteins"},{"issue":"3","key":"9800_CR27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/prot.20217","volume":"57","author":"I Schellhammer","year":"2004","unstructured":"Schellhammer I, Rarey M (2004) FlexX-Scan: fast, structure-based virtual screening. Proteins 57(3):504\u2013517","journal-title":"Proteins"},{"issue":"6","key":"9800_CR28","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.bmc.2005.10.022","volume":"14","author":"N Foloppe","year":"2006","unstructured":"Foloppe N, Fisher LM, Francis G, Howes R, Kierstan P, Potter A (2006) Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. Bioorg Med Chem 14(6):1792\u20131804","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"9800_CR29","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1021\/jm061247v","volume":"50","author":"ZF Tao","year":"2007","unstructured":"Tao ZF, Wang L, Stewart KD, Chen Z, Gu W et al (2007) Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J Med Chem 50(7):1514\u20131527","journal-title":"J Med Chem"},{"issue":"18","key":"9800_CR30","doi-asserted-by":"crossref","first-page":"9997","DOI":"10.1073\/pnas.96.18.9997","volume":"96","author":"ID Kuntz","year":"1999","unstructured":"Kuntz ID, Chen K, Sharp KA, Kollman PA (1999) The maximal affinity of ligands. Proc Natl Acad Sci USA 96(18):9997\u201310002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"9800_CR31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","volume":"9","author":"AL Hopkins","year":"2004","unstructured":"Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9(10):430\u2013431","journal-title":"Drug Discov Today"},{"issue":"2","key":"9800_CR32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","volume":"13","author":"AL Hopkins","year":"2014","unstructured":"Hopkins AL, Keser\u00fc GM, Leeson PD, Rees DC, Reynolds CH (2014) The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov 13(2):105\u2013121","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"9800_CR33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/17460441.2.4.469","volume":"2","author":"C Abad-Zapatero","year":"2007","unstructured":"Abad-Zapatero C (2007) Ligand efficiency indices for effective drug discovery. Expert Opin Drug Discov 2(4):469\u2013488","journal-title":"Expert Opin Drug Discov"},{"key":"9800_CR34","unstructured":"Symyx Software: MACCS structural keys San Ramon, CA"},{"issue":"14","key":"9800_CR35","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1021\/jm0300330","volume":"46","author":"SL McGovern","year":"2003","unstructured":"McGovern SL, Shoichet BK (2003) Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J Med Chem 46(14):2895\u20132907","journal-title":"J Med Chem"},{"key":"9800_CR36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/363368a0","volume":"363","author":"N Walworth","year":"1993","unstructured":"Walworth N, Davey S, Beach D (1993) Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature (Lond.) 363:368\u2013371","journal-title":"Nature (Lond.)"},{"key":"9800_CR37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0960-9822(95)00234-X","volume":"5","author":"AM Carr","year":"1995","unstructured":"Carr AM, Moudjou M, Bentley NJ, Hagan IM (1995) The chk1 pathway is required to prevent mitosis following cell-cycle arrest at \u2018start\u2019. Curr Biol 5:1179\u20131190","journal-title":"Curr Biol"},{"key":"9800_CR38","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1083\/jcb.142.6.1559","volume":"142","author":"A Kumagai","year":"1998","unstructured":"Kumagai A, Guo Z, Emami KH, Wang S, Dunphy WG (1998) The Xenopus Chk1 protein kinase mediates a caffeine-sensitive pathway of checkpoint control in cell-free extracts. J Cell Biol 142:1559\u20131569","journal-title":"J Cell Biol"},{"key":"9800_CR39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1091\/mbc.10.4.833","volume":"10","author":"B Furnari","year":"1999","unstructured":"Furnari B, Blasina A, Boddy M, McGowan C, Russell P (1999) Cdc25 inhibited in vivo and in vitro by checkpoint kinases Cds1 and Chk1. Mol Biol Cell 10:833\u2013845","journal-title":"Mol Biol Cell"},{"issue":"1","key":"9800_CR40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1535-7163.MCT-08-0662","volume":"8","author":"LA Parsels","year":"2009","unstructured":"Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD et al (2009) Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 8(1):45\u201354","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"9800_CR41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.19240","volume":"13","author":"Y Tang","year":"2012","unstructured":"Tang Y, Dai Y, Grant S, Dent P (2012) Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol Ther 13(6):379\u2013388","journal-title":"Cancer Biol Ther"},{"issue":"15\u201316","key":"9800_CR42","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.drudis.2006.06.016","volume":"11","author":"GM Keseru","year":"2006","unstructured":"Keseru GM, Makara GM (2006) Hit discovery and hit-to-lead approaches. Drug Discov Today 11(15\u201316):741\u2013748","journal-title":"Drug Discov Today"},{"key":"9800_CR43","doi-asserted-by":"crossref","unstructured":"Daud A, Springett GM, Mendelson DS, Munster PN, Goldman JR et al. (2010) A Phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. J Clin Oncol 28 (Suppl): Abstract 3064","DOI":"10.1200\/jco.2010.28.15_suppl.3064"},{"key":"9800_CR44","doi-asserted-by":"crossref","unstructured":"McNeely SC, Burke TF, DurlandBusbice S, Barnard DS, Marshall MS, Bence AK, Beckmann RP (2011). LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents. AACR-NCI-EORTC International Conference: Mol Cancer Ther 10 (Suppl 1): Abstract A108","DOI":"10.1158\/1535-7163.TARG-11-A108"},{"key":"9800_CR45","unstructured":"Wu W, Bi C, Bence AK, Um SL, Yan B, Starling JJ, Marshall MS, Beckmann RP (2012) Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model. AACR 103rd Annual Meeting2012. Cancer Res 72 (Suppl 1): Abstract 1776"},{"key":"9800_CR46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1535-7163.MCT-09-0938","volume":"9","author":"MI Walton","year":"2010","unstructured":"Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A et al (2010) The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther 9:89\u2013100","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"9800_CR47","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1016\/j.bmc.2006.03.021","volume":"14","author":"N Foloppe","year":"2006","unstructured":"Foloppe N, Fisher LM, Howes R, Potter A, Robertson AG, Surgenor AE (2006) Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening. Bioorg Med Chem 14(14):4792\u20134802","journal-title":"Bioorg Med Chem"},{"issue":"14","key":"9800_CR48","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1016\/j.bmcl.2010.05.096","volume":"20","author":"TP Matthews","year":"2010","unstructured":"Matthews TP, McHardy T, Klair S, Boxall K, Fisher M et al (2010) Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. Bioorg Med Chem Lett 20(14):4045\u20134049","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"9800_CR49","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.bmcl.2012.01.110","volume":"22","author":"VY Dudkin","year":"2012","unstructured":"Dudkin VY, Rickert K, Kreatsoulas C, Wang C, Arrington KL et al (2012) Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates. Bioorg Med Chem Lett 22(7):2609\u20132612","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-014-9800-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10822-014-9800-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-014-9800-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T04:07:48Z","timestamp":1565928468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10822-014-9800-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["9800"],"URL":"https:\/\/doi.org\/10.1007\/s10822-014-9800-9","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}